Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Joseph Casalini"'
Autor:
Kate C. Gillespie, Thomas L. Deckwerth, Richard A. Klinghoffer, Joseph Casalini, Joyoti Dey, Edward F. Kleinman, Sally Ditzler, Marc Grenley, Emily Beirne, Chantel P. Dixon, Angela Merrell, Connor Burns, William S. Kerwin
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Scientific Reports
Scientific Reports
Aberrant regulation of BCL-2 family members enables evasion of apoptosis and tumor resistance to chemotherapy. BCL-2 and functionally redundant counterpart, MCL-1, are frequently over-expressed in high-risk diffuse large B-cell lymphoma (DLBCL). Whil
Autor:
Derek Thirstrup, Jason Frazier, Ilona Tretyak, Richard A. Klinghoffer, Sue E. Knoblaugh, Joseph Casalini, J. G. Ward, Emily Beirne, C. D. Tripp, Sally Ditzler
Publikováno v:
Veterinary and Comparative Oncology. 15:754-763
Spontaneously occurring soft tissue sarcoma (STS) is relatively common in canine cancer patients. Because of the similarities to human disease, canine STSs are a valuable and readily available resource for the study of new therapeutics. In this study
Autor:
Richard A. Klinghoffer, Sally Ditzler, Marc Grenley, Michael Carleton, Joyoti Dey, Ilona Tretyak, Jason Frazier, William S. Kerwin, Daniel W. Pierce, Derek Thirstrup, Joseph Casalini
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0158617 (2016)
PLoS ONE
PLoS ONE
While advances in high-throughput screening have resulted in increased ability to identify synergistic anti-cancer drug combinations, validation of drug synergy in the in vivo setting and prioritization of combinations for clinical development remain
Autor:
Richard A. Klinghoffer, Joseph Casalini, Emily J. Girard, Michael Carleton, Kyle Pedro, Thomas L. Deckwerth, Shelli M. Morris, Ilona Tretyak, Andrew D. Strand, Emily Beirne, James M. Olson, Sheng You, Derek Thirstrup, Oliver W. Press, Sally Ditzler, Korashon L. Watts, William S. Kerwin, Jason Frazier, Alicia Moreno-Gonzalez, Rajesh Chopra, Jessica A. Bertout, Joyoti Dey, Mandana Veiseh, Beryl A. Hatton, Ellen Filvaroff, Marc Grenley, Karri A. Meleo, S. Bahram Bahrami
A fundamental problem in cancer drug development is that antitumor efficacy in preclinical cancer models does not translate faithfully to patient outcomes. Much of early cancer drug discovery is performed under in vitro conditions in cell-based model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::036e0944789fee2391dea23e9e214e73
https://europepmc.org/articles/PMC4770902/
https://europepmc.org/articles/PMC4770902/
Autor:
Matt Biery, Joyoti Dey, Derek Thirstrup, Richard A. Klinghoffer, Joseph Casalini, Sally Ditzler, Angela Merrell, Marc Grenley
Publikováno v:
Cancer Research. 76:2835-2835
Triple negative breast cancer (TNBC) is a highly heterogeneous disease, notoriously challenging to treat with standard chemotherapy options, and therefore is an area of intense focus for discovery of novel effective combination therapies. Here we use
Autor:
Richard A. Klinghoffer, Jessica A. Bertout, Alicia Moreno Gonzalez, Sally Ditzler, Jason Frazier, Nathan Caffo, William S. Kerwin, Joseph Casalini
Publikováno v:
Cancer Research. 75:2020-2020
We report the initial clinical findings of a device platform to test multiple therapeutic options simultaneously in individual living tumors within a clinical patient population, detailing for the first time comparative effects of different drugs wit
Toxicity-sparing in-tumor profiling of multiple drugs simultaneously in canine patients with sarcoma
Autor:
Richard A. Klinghoffer, Jessica A. Bertout, Joseph Casalini, Alicia Moreno-Gonzalez, Sally Ditzler, Korashon Watts, William S. Kerwin, Thomas L. Deckwerth, Jason Frazier
Publikováno v:
Journal of Clinical Oncology. 33:e22177-e22177
e22177 Background: Cancer drug developers face a fundamental challenge in the way new candidate drugs are evaluated. Early stage compounds are tested in preclinical models that lack important compo...
Autor:
Michael Carleton, Jason Frazier, Richard A. Klinghoffer, Alicia Moreno-Gonzalez, Sally Ditzler, Marc Grenley, James M. Olson, Beryl A. Hatton, Joseph Casalini, William S. Kerwin, Nathan Caffo, Ilona Tretyak, Joyoti Dey, Nathan Hedin
Publikováno v:
Clinical Cancer Research. 21:A39-A39
Assessment of anti-cancer drug efficacy is an imprecise and challenging undertaking. Early candidate selection is typically based on results from systemically treated animal models and later by performance in human trials where patients are exposed t
Abstract 3129: A platform to assess multiple therapy options simultaneously in a patient's own tumor
Autor:
Nathan Caffo, Joyoti Dey, Nathan Hedin, Richard A. Klinghoffer, Beryl A. Hatton, Michael Carleton, Ilona Tretyak, Sally Ditzler, Jason Frazier, Alicia Moreno-Gonzalez, James M. Olson, Marc Grenley, Daniel T. Pierce, Joseph Casalini, Ellen Filvaroff
Publikováno v:
Cancer Research. 74:3129-3129
Proper selection of anti-cancer agents at the earliest stage of patient treatment following diagnosis of disease relapse is expected to substantially impact clinical response to treatment. Currently, genomic approaches to personalized cancer treatmen